Updated Results From Cohort C of CARTITUDE-2: Ciltacabtagene Autoleucel for Progressive Multiple Myeloma

By: Julia Fiederlein Cipriano
Posted: Friday, January 27, 2023

Adam D. Cohen, MD, of the University of Pennsylvania, Philadelphia, and colleagues conducted a study to assess the B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell therapy ciltacabtagene autoleucel in patients with multiple myeloma. The updated follow-up data from cohort C of the phase II CARTITUDE-2 study, which were presented during the 2022 American Society of Hematology (ASH) Annual Meeting and Exposition (Abstract 2028), suggested this agent may inform treatment plans, sequencing, and washout periods in those with previous exposure to a noncellular anti-BCMA therapy.

After undergoing lymphodepletion, a total of 20 patients (antibody-drug conjugate–exposed: n = 13; bispecific antibody–exposed: n = 7) received a single ciltacabtagene autoleucel infusion at a target dose of 0.75 x 10⁶ CAR-positive T cells/kg. Of the 10 patients evaluable for measurable residual disease (MRD), 7 achieved MRD negativity at a threshold of 10^-5 cells. The overall response rate was 61.5% in patients treated with an antibody-drug conjugate, 57.1% in those who received a bispecific antibody, and 60.0% in the full cohort. The median durations of response were 12.8, 8.2, and 12.8 months; the median durations of progression-free survival were 9.5, 5.3, and 9.1 months, respectively.

Responders had a shorter median duration of exposure to their last anti-BCMA agent compared with nonresponders (29.5 vs. 63.5 days). The median duration of time from the last anti-BCMA agent exposure to apheresis was longer in responders (161.0 vs. 56.5 days).

The most common adverse events were hematologic. A total of 60% of patients had cytokine-release syndrome; the median time to onset was 7.5 days, and the median duration was 6.0 days. Immune effector cell–associated neurotoxicity syndrome, which was reported in 20% of patients, had a median time to onset of 9 days and a median duration of 7 days. No patients experienced movement or neurocognitive treatment-emergent adverse events. A total of 12 deaths were reported.

Disclosure: For full disclosures of the study authors, visit ash.confex.com.

2022 ASH Annual Meeting and Exposition

---